FDA Approved: ORSERDU — Original Application (Stemline Therapeutics, Inc.)

View source ↗

Summary

FDA approved ORSERDU (elacestrant) for ER-positive, HER2-negative advanced or metastatic breast cancer following aromatase inhibitor therapy, based on pivotal P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Orserdu (Elacestrant)

Snippet

ORIG AP for ORSERDU (ELACESTRANT)